TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ConvaTec ( (GB:CTEC) ) just unveiled an announcement.
ConvaTec Group PLC has completed its share buyback program, purchasing 1,912,745 ordinary shares through UBS AG London Branch, as part of a $300 million initiative announced earlier in August 2025. The shares, bought at an average price of 230.19 pence, will be held in treasury, and this transaction concludes the buyback program, potentially impacting the company’s share value and market positioning.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing advanced wound care, ostomy care, continence and critical care, and infusion care products. The company aims to improve the lives of patients by offering innovative solutions and services in these areas.
Average Trading Volume: 9,593,529
Technical Sentiment Signal: Hold
Current Market Cap: £4.54B
For a thorough assessment of CTEC stock, go to TipRanks’ Stock Analysis page.